Achieved $30 million milestone from Roche and Genentech for delivering a whole-genome map of microglial immune cells—the ...

Learn more about whether Recursion Pharmaceuticals, Inc. or Viridian Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Recursion CEO Chris Gibson is out after 12 years as the ambitious "techbio" company positions itself for its next phase of AI drug discovery.

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...

Recursion Pharmaceuticals, Inc (($RXRX)) has held its Q3 earnings call. Read on for the main highlights of the call. Recursion Pharmaceuticals, ...

Reports Q3 revenue $5.2M, consensus $19.36M. Cash, cash equivalents and restricted cash were $667.1M as of September 30, compared to $603.0M as of ...

AMD CEO and Chairman Dr. Lisa Su updated the size of the total addressable market for the AI data center and now sees it ...

The traditional model of one-time sales is giving way to continuous value delivery through software, altering how companies ...

Stories and analogies can help rheumatology patients understand the complexities of their conditions and improve medication ...

To investigate this, we simultaneously recorded the brain activity from pairs of players as they played 480 rounds of rock, ...

You don’t need time to rewatch all seven seasons. Just one episode of Gilmore Girls is enough to feel like you’ve come home.

Supply Chain Management Review, reposted here, a Rutgers Business School graduate student (Master of Supply Chain Analytics) explains how as disruptions become structural rather than episodic, ...